JP2018526345A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526345A5 JP2018526345A5 JP2018504281A JP2018504281A JP2018526345A5 JP 2018526345 A5 JP2018526345 A5 JP 2018526345A5 JP 2018504281 A JP2018504281 A JP 2018504281A JP 2018504281 A JP2018504281 A JP 2018504281A JP 2018526345 A5 JP2018526345 A5 JP 2018526345A5
- Authority
- JP
- Japan
- Prior art keywords
- cycloserine
- composition
- therapeutic agent
- salt
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 13
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 9
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims 8
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 239000002243 precursor Substances 0.000 claims 3
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 208000029560 autism spectrum disease Diseases 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010008748 Chorea Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000005374 Poisoning Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 229960004047 acamprosate Drugs 0.000 claims 1
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims 1
- BUVGWDNTAWHSKI-UHFFFAOYSA-L acamprosate calcium Chemical compound [Ca+2].CC(=O)NCCCS([O-])(=O)=O.CC(=O)NCCCS([O-])(=O)=O BUVGWDNTAWHSKI-UHFFFAOYSA-L 0.000 claims 1
- 229960001157 acamprosate calcium Drugs 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 150000003863 ammonium salts Chemical class 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000006399 behavior Effects 0.000 claims 1
- 230000004641 brain development Effects 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 208000024825 childhood disintegrative disease Diseases 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 210000000805 cytoplasm Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 125000004185 ester group Chemical group 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000013016 learning Effects 0.000 claims 1
- 229960004502 levodopa Drugs 0.000 claims 1
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 235000020830 overeating Nutrition 0.000 claims 1
- 231100000572 poisoning Toxicity 0.000 claims 1
- 230000000607 poisoning effect Effects 0.000 claims 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 230000005062 synaptic transmission Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 150000003751 zinc Chemical class 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021103459A JP2021152060A (ja) | 2015-08-04 | 2021-06-22 | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200864P | 2015-08-04 | 2015-08-04 | |
| US62/200,864 | 2015-08-04 | ||
| PCT/US2016/045547 WO2017024129A1 (en) | 2015-08-04 | 2016-08-04 | Combination therapy using acamprosate and d-cycloserine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103459A Division JP2021152060A (ja) | 2015-08-04 | 2021-06-22 | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018526345A JP2018526345A (ja) | 2018-09-13 |
| JP2018526345A5 true JP2018526345A5 (enExample) | 2019-09-19 |
Family
ID=57944041
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018504281A Pending JP2018526345A (ja) | 2015-08-04 | 2016-08-04 | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 |
| JP2021103459A Pending JP2021152060A (ja) | 2015-08-04 | 2021-06-22 | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021103459A Pending JP2021152060A (ja) | 2015-08-04 | 2021-06-22 | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20180221315A1 (enExample) |
| EP (1) | EP3331518A4 (enExample) |
| JP (2) | JP2018526345A (enExample) |
| KR (1) | KR20180034442A (enExample) |
| AU (2) | AU2016303610A1 (enExample) |
| CA (1) | CA2993614A1 (enExample) |
| HK (1) | HK1255584A1 (enExample) |
| IL (1) | IL257035A (enExample) |
| SG (1) | SG10201914045QA (enExample) |
| WO (1) | WO2017024129A1 (enExample) |
| ZA (1) | ZA201800558B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017024129A1 (en) * | 2015-08-04 | 2017-02-09 | Confluence Pharmaceuticals, Llc | Combination therapy using acamprosate and d-cycloserine |
| IL270654B2 (en) | 2017-05-17 | 2024-07-01 | Confluence Pharmaceuticals Llc | Formulations of homotaurines and salts thereof |
| CN110996946A (zh) | 2017-05-25 | 2020-04-10 | 格莱泰施有限责任公司 | 用于治疗创伤后应激障碍的制剂 |
| US11291654B2 (en) * | 2018-09-13 | 2022-04-05 | Syneurx International (Taiwan) Corp. | Formulations of cycloserine compounds and applications thereof |
| JP2025069475A (ja) * | 2022-03-08 | 2025-05-01 | ソシウム株式会社 | Ｔｄｐ－４３の凝集の抑制剤、ｔｄｐ－４３が過剰発現している細胞の細胞死の抑制剤、及びｔｄｐ－４３の凝集を伴う疾患の治療又は予防剤 |
| CN119212703A (zh) * | 2023-04-27 | 2024-12-27 | 寿协株式会社 | 肌萎缩性侧索硬化症的治疗剂或预防剂 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1073432T1 (de) * | 1998-04-14 | 2002-02-07 | The General Hospital Corp., Boston | Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| JP2010532331A (ja) * | 2007-07-05 | 2010-10-07 | アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） | 抗痙攣医薬組成物 |
| DK2395990T3 (en) * | 2009-02-12 | 2015-02-23 | Univ Indiana Res & Tech Corp | Material and methods for the treatment of developmental disorders comprising co-morbid and idiopathic autism |
| WO2010099217A1 (en) * | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| KR20130002292A (ko) * | 2011-06-28 | 2013-01-07 | 주식회사 비보존 | 다중 타겟팅의 상승 효과를 유발하는 유효물질의 조합 및 그 용도 |
| US10709668B2 (en) * | 2015-05-04 | 2020-07-14 | Confluence Pharmaceuticals, Llc | Sprinkle formulations of acamprosate |
| WO2017024129A1 (en) * | 2015-08-04 | 2017-02-09 | Confluence Pharmaceuticals, Llc | Combination therapy using acamprosate and d-cycloserine |
-
2016
- 2016-08-04 WO PCT/US2016/045547 patent/WO2017024129A1/en not_active Ceased
- 2016-08-04 SG SG10201914045QA patent/SG10201914045QA/en unknown
- 2016-08-04 AU AU2016303610A patent/AU2016303610A1/en not_active Abandoned
- 2016-08-04 HK HK18114711.9A patent/HK1255584A1/zh unknown
- 2016-08-04 KR KR1020187002542A patent/KR20180034442A/ko not_active Ceased
- 2016-08-04 CA CA2993614A patent/CA2993614A1/en not_active Abandoned
- 2016-08-04 EP EP16833870.5A patent/EP3331518A4/en not_active Withdrawn
- 2016-08-04 US US15/749,705 patent/US20180221315A1/en not_active Abandoned
- 2016-08-04 JP JP2018504281A patent/JP2018526345A/ja active Pending
-
2018
- 2018-01-21 IL IL257035A patent/IL257035A/en unknown
- 2018-01-26 ZA ZA201800558A patent/ZA201800558B/en unknown
-
2020
- 2020-06-02 US US16/890,533 patent/US20200360316A1/en not_active Abandoned
-
2021
- 2021-06-22 JP JP2021103459A patent/JP2021152060A/ja active Pending
-
2022
- 2022-04-01 AU AU2022202218A patent/AU2022202218A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018526345A5 (enExample) | ||
| CY1121781T1 (el) | Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης της ρασαγιλινης και χρησεις αυτων | |
| MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
| HRP20120317T1 (hr) | Spojevi morfinana | |
| WO2017123884A8 (en) | Heterocyclic compounds as rsv inhibitors | |
| JP2018514544A5 (enExample) | ||
| JP2018520189A5 (enExample) | ||
| GEP201706780B (en) | Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c | |
| CA2923685A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| BR112015010396A2 (pt) | terapia de combinação | |
| JP2015519404A5 (enExample) | ||
| JP2018516906A5 (enExample) | ||
| BR112018012870A2 (pt) | métodos e composições para o tratamento de transtornos relacionados à crise | |
| JP2020500875A5 (enExample) | ||
| GB201021104D0 (en) | Novel compounds for the treatment of neurodegenerative diseases | |
| BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
| HRP20110497T4 (hr) | Postupci za primjenu kompozicija aminopiridina sa produženim oslobađanjem | |
| JP2012523437A5 (enExample) | ||
| SI2413933T1 (en) | 2,4,6-TRIUFLORO-N- (6- (1-METHYL-PIPERIDIN-4-CARBONYL) -PYRIDIN-2-YL)-BENZAMIDE FOR THRESHOLD OF MIGRINE OVER ORAL OR INTRAVEN | |
| DK2091942T3 (da) | Substituerede pyrazinderivater til anvendelse som en medicin | |
| RU2009131745A (ru) | Лекарственное средство для профилактического и/или терапевтического лечения деменции по типу альцгеймера | |
| WO2007135131A8 (en) | Substituted pyrazinone derivatives for use as a medicine | |
| NZ589618A (en) | PAEDIATRIC COMPOSITIONS COMPRISING 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol FOR TREATING MULTIPLE SCLEROSIS | |
| TW200731975A (en) | Novel combinations of medicaments for the treatment of respiratory diseases | |
| WO2014047288A3 (en) | Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof |